Opportunity
Simpler Grants.gov #NOT-DK-26-316
NIH Notice of Intent: Single Source Continuation of Integrated Islet Distribution Program (IIDP)
Buyer
National Institutes of Health
Posted
May 12, 2025
Identifier
NOT-DK-26-316
NAICS
541714, 541715
The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is announcing its intent to continue the Integrated Islet Distribution Program (IIDP) via a single source cooperative agreement. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Anticipated Awardee: - Beckman Research Institute/City of Hope - Program Overview: - Continuation of the Integrated Islet Distribution Program (IIDP) - Distribution of human islets to biomedical researchers - Management of investigator eligibility, islet availability, and cost recovery - Standardized phenotypic and genotypic analyses of islets - Products/Services Requested: - Research services related to live human islet distribution and analysis - No specific products, part numbers, or quantities are listed - Unique Requirements: - Single source cooperative agreement (no competition anticipated) - Essential support for diabetes research and therapy development - No applications are being solicited at this time; this is a preparatory notice - OEMs Highlighted: - No commercial OEMs are specified; Beckman Research Institute/City of Hope is the anticipated service provider - Place of Performance: - National Institutes of Health (federal office)
Description
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to publish a Notice of Funding Opportunity to solicit applications for research on distributing human islets. The program aims to renew the Integrated Islet Distribution Program (IIDP) through a single source cooperative agreement with Beckman Research Institute/City of Hope. The IIDP facilitates the distribution of human islets to biomedical researchers by partnering with islet isolation facilities, managing investigator eligibility, islet availability, cost recovery, and standardized analyses. Human islets are essential for diabetes research to advance understanding and develop new therapies. Applications are not currently being solicited; this notice allows potential applicants time to prepare.